Twice-Daily vs. Once-Daily Dosing with 0.075% Bromfenac in DuraSite: Outcomes from a 14-Day Phase 2 Study
Crossref DOI link: https://doi.org/10.1007/s40123-017-0102-x
Published Online: 2017-08-17
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Trattler, William
Hosseini, Kamran
Funding for this research was provided by:
InSite Vision